Pre-existing T cell memory as a risk factor for severe COVID-19 in the elderly

- Petra Bacher, 1,2,14 Elisa Rosati², Daniela Esser³, Gabriela Rios Martini, 1,2 Carina Saggau¹, 3
- 4 Esther Schiminsky¹, Justina Dargvainiene³, Ina Schöder³, Imke Wieters⁴, Yascha
- 5 Khodamoradi⁴ Fabian Eberhardt⁴, Holger Neb⁵, Michael Sonntagbauer⁵, Maria J.G.T.
- Vehreschild⁴, Claudio Conrad⁶, Florian Tran^{2,7}, Philip Rosenstiel², Robert Markewitz⁸, Klaus-6
- 7 Peter Wandinger⁸, Jan Rybniker^{9,10,11}, Matthias Kochanek⁹, Frank Leypoldt³, Oliver A.
- Cornely^{9,10,11,12,13}, Philipp Koehler^{9,10,13}, Andre Franke² and Alexander Scheffold¹ 8
- 10 ¹Institute of Immunology, Christian-Albrechts-University of Kiel & UKSH Schleswig-Holstein,
- 11 Kiel, Germany

1 2

9

- 12 ²Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
- 13 ³Neuroimmunology, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein,
- 14 Kiel, Germany
- 15 ⁴Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt & Goethe
- 16 University Frankfurt, Frankfurt am Main, Germany.
- 17 ⁵Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University
- 18 Hospital Frankfurt, Frankfurt am Main, Germany.
- 19 ⁶Department of Internal Medicine, Hospital of Preetz, Preetz, Germany
- 20 ⁷ Department of Internal Medicine I, UKSH Kiel, Germany
- 21 ⁸Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Lübeck, Germany
- 22 ⁹University of Cologne, Medical Faculty and University Hospital Cologne, Department I of
- 23 Internal Medicine, 50937 Cologne, Germany
- 24 ¹⁰Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931, Cologne,
- 25 Germany
- 26 ¹¹University of Cologne, Medical Faculty and University Hospital Cologne, German Center for
- 27 Infection Research (DZIF), Partner Site Bonn-Cologne, 50937 Cologne, Germany.
- ¹²Clinical Trials Centre Cologne, ZKS Köln, 50935 Cologne, Germany. 28
- 29 ¹³University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-
- Associated Diseases (CECAD), 50937 Cologne, Germany 30
- ¹⁴Lead contact 31

Corresponding Author

34 Petra Bacher

- Christian-Albrechts Universität zu Kiel & Universitätsklinik Schleswig-Holstein 35
- Institute of Immunology & Insitute of Clinical Molecular Biology 36
- Arnold-Heller-Str. 3, 24105 Kiel, Germany 37
- 38
- Phone: +49 (0) 431 500-31005
 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 Fax: +49 (0) 431 500-31004
- 39
- 40 Email: p.bacher@ikmb.uni-kiel.de

Summary

 Coronavirus disease 2019 (COVID-19) displays high clinical variability but the parameters that determine disease severity are still unclear. Pre-existing T cell memory has been hypothesized as a protective mechanism but conclusive evidence is lacking. Here we demonstrate that all unexposed individuals harbor SARS-CoV-2-specific memory T cells with marginal cross-reactivity to common cold corona and other unrelated viruses. They display low functional avidity and broad protein target specificities and their frequencies correlate with the overall size of the CD4+ memory compartment reflecting the "immunological age" of an individual. COVID-19 patients have strongly increased SARS-CoV-2-specific inflammatory T cell responses that are correlated with severity. Strikingly however, patients with severe COVID-19 displayed lower TCR functional avidity and less clonal expansion. Our data suggest that a low avidity pre-existing T cell memory negatively impacts on the T cell response quality against neoantigens such as SARS-CoV-2, which may predispose to develop inappropriate immune reactions especially in the elderly. We propose the immunological age as an independent risk factor to develop severe COVID-19.

Key points

- Pre-existing SARS-CoV-2-reactive memory T cells are present in all humans, but have low functional avidity and broad target specificities
- Pre-existing memory T cells show only marginal cross-reactivity to common cold corona viruses
- Frequencies of pre-existing memory T cells increase with the size of the CD4+ memory compartment reflecting the "immunological age" of the individual
- Low-avidity and polyclonal, but strongly enhanced SARS-CoV-2 specific T cell responses develop in severe COVID-19, suggesting their origin from pre-existing memory
- The immunological age may represent a risk factor to develop severe COVID-19

71

72 73

74

75

76

77

78

79

80

81

82

83

84

85 86

87

88 89

90

91

92

93

94

95 96

97

98

99

100

101

102

103

104

105

106

107

Introduction COVID-19 displays remarkable disparity of clinical symptoms, ranging from asymptomatic or mild disease frequently observed in children and younger adults to severe clinical symptoms associated with high mortality mainly in elderly and high-risk patients. Differences in the immune response may contribute to this diverse pathology. Severe disease is characterized by hyperinflammation, suggesting that exaggerated immune reactions are part of COVID-19 pathogenesis. However, it is currently not clear which type of adaptive immunity to SARS-CoV-2 is protective or detrimental. Thus, there is an enormous interest to decipher the anti-SARS-CoV-2 response, both to define parameters of immune protection versus pathology, as well as for the design of effective vaccination strategies. SARS-CoV-2-specific CD4+ T cells are prime candidates to be involved in this process. They are central organizers of anti-viral immune responses while uncontrolled T cell responses may cause pathology. Severe lymphopenia accompanies severe disease and T cell reappearance correlates with patient recovery (Huang et al., 2020; Tan et al., 2020; Wang et al., 2020; Yang et al., 2020). Markers of T cell activation were found to be increased on total (Diao et al., 2020; Sekine et al., 2020; Wilk et al., 2020; Zheng et al., 2020), as well as on SARS-CoV-2-specific T cells (Braun et al., 2020; Sekine et al., 2020). Overall COVID-19 patients seem to develop robust Th1-like SARS-CoV-2-specific CD4+ T cell responses focused on spike, membrane and nucleocapsid (Ncap) proteins (Grifoni et al., 2020). Increased frequencies of SARS-CoV-2-specific T cells have been correlated with more severe disease (Anft et al., 2020; Peng et al., 2020) supporting the idea that exaggerated CD4+ T cell responses may contribute to the hyperinflammation. However, the factors which determine the magnitude as well as the quality of the CD4+ T cell response and how this relates to predisposition and/ or manifestation of severe disease remains unknown. In particular, the effect of aging is discussed, since the risk to develop severe COVID-19 dramatically increases in the elderly. Several studies have observed that a certain fraction of un-exposed donors have pre-existing SARS-CoV-2-reactive T cells (Braun et al., 2020; Grifoni et al., 2020; Le Bert et al., 2020; Mateus et al., 2020; Meckiff et al., 2020; Sekine et al., 2020; Weiskopf et al., 2020) which contained at least some T cells cross-reactive against selected peptides with homology to related common cold corona virus strains (CCCoV) (Braun et al., 2020; Mateus et al., 2020). From this it was hypothesized that encounter with CCCoV may provide protective crossreactive memory especially in younger patients, where infections with CCCoV are especially prevalent. However, data on the prevalence of CD4+ T cell responses against CCCoV in humans are lacking. Furthermore, pre-existing immunity has also been described for several other pathogens and neoantigens (Bacher et al., 2013; Campion et al., 2014; Kwok et al., 2012; Su

et al., 2013) with variable consequences, from protective to harmful (Bacher et al., 2019:

Greiling et al., 2018; Koutsakos et al., 2019; Sridhar et al., 2013; Welsh et al., 2010; Woodland and Blackman, 2006). Thus its impact may depend on the T cells functional characteristics, the specific antigen- or pathogen-context (Sette and Crotty, 2020), and age (Woodland and Blackman, 2006). Such functional characteristics of SARS-CoV-2-specific T cells in severe *versus* mild COVID-19 and unexposed individuals are still poorly described. Specifically, the prevalence of the putative cross-reactive T cells within unexposed donors and COVID-19 patients and in different age groups, their phenotypic and functional characteristics, as well as the inducing antigen(s) are unknown.

Here we show that pre-existing memory T cells are present in all unexposed donors and increased in the elderly, but not primarily driven by CCCoVs. Pre-existing SARS-CoV-2-specific memory T cells possess only low TCR avidity, suggesting impaired functionailty. This functional impairment is closely mirrored in T cells from severe COVID-19 patients in contrast to mild disease, suggesting that they may originate from pre-existing memory T cells. Thus we suggest the immunological age as a potential risk factor for severe COVID-19.

Results

123

124

125126

127

128129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144145

146

147

148149

150

151

152153154

155

156157158

159

160

161

162

163

Strongly increased frequencies of human SARS-CoV-2-reactive CD4+ T cells against the spike, membrane and Ncap proteins in COVID-19 patients

To characterize the human T cell response against SARS-CoV-2, we analyzed T cells reactive against a panel of 12 different SARS-CoV-2 proteins. SARS-CoV-2-reactive CD4+ T cells were detected based on the up-regulation of CD154+ (CD40L) following 7h ex vivo stimulation of PBMCs with overlapping peptide pools of the different proteins and subsequent magnetic enrichment (Antigen-reactive T cell enrichment, ARTE) (Bacher et al., 2016; Bacher et al., 2019) (Figure S1A). SARS-CoV-2 exposure versus non-exposure of blood donors was verified by SARS-CoV-2 PCR and/ or serology testing (Table S1). The response of COVID-19 patients was mainly directed against three proteins, spike, membrane and nucleocapsid (Ncap), as previously suggested (Grifoni et al., 2020), as well as to lower extent and with more variability between donors against AP3a, ORF9b, NS6, NS7a and NS8 (Figure 1A, B). We observed no differences in the reactivity against the N-terminal or C-terminal part of the spike protein in COVID-19 patients. The frequencies of reactive cells against single or pooled spike, membrane and Ncap, were strongly increased in patients versus unexposed individuals (Figure 1C), whereas no differences were detected against a pool of Influenza A H1N1 proteins (containing HA, MP1, MP2, NP and NA), as a control antigen. In contrast to previous reports suggesting pre-existing memory only in a subset of unexposed individuals, the sensitive detection by ARTE identified SARS-CoV-2 reactive T cells in all unexposed donors albeit at low and variable frequencies ranging from 1 in 10⁻⁵-10⁻³ (Figure 1A-C). However, while typically >80-90% of SARS-CoV-2 reactive T cells in COVID-19 patients were directed against spike, membrane and Ncap, the response in unexposed donors was much more variable and directed against multiple proteins (Figure 1D) (Grifoni et al., 2020; Le Bert et al., 2020). The specificity of the SARS-CoV-2-reactive cells in unexposed as well as exposed donors was confirmed by high reactivity of sorted and expanded CD154+

SARS-CoV-2 reactive T cells of COVID-19 patients show an activated Th1/Tfh-like signature

T cells towards SARS-CoV-2, but not control antigens (Figure S1B, C).

SARS-CoV-2 reactive cells from COVID-19 patients *versus* unexposed individuals displayed increased expression of the acute and chronic activation markers Ki-67 and CD38 (Figure 2A), as reported by others (Braun et al., 2020; Sekine et al., 2020). The expression of both markers declined with time after infection, but not the frequencies of reactive T cells (Figure 2B, C). We also detected slightly increased relative and strongly increased absolute production of inflammatory cytokines in COVID-19 patients, such as IL-2, IFN-γ and IL-21 compared to

164165

166

167

168

169

170

171

172173

174 175

176177

178

179

180

181

182

183

184

185186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

unexposed donors, as well as a slightly higher production of IL-10 (Figure 2D, E). While inflammatory cytokines increased with time after infection, IL-10 was mainly produced during active disease (Figure S2A), suggesting a counter-regulatory mechanism during acute infection. In addition, SARS-CoV-2 reactive T cells expressed stably high levels of PD-1 (CD279) (Figure 2D, E and S2A). Compared to other anti-viral reponses, production of TNF- α , IFN- γ and IL10 was rather reduced in convalescent COVID-19 patients, while IL-21 and PD-1 were highly increased (Figure 2F, Figure S2B). We observed no differences in the cytokine response or phenotype between the individual SARS-CoV-2 proteins (Figure 2F, Figure S2B).

Single-cell RNA sequencing identifies similar T cell clusters in COVID-19 and unexposed donors

To obtain a deeper insight into the cellular composition of SARS-CoV-2-specific T cells and their molecular patterns we next performed single-cell RNA sequencing of ex vivo FACSpurified SARS-CoV-2 reactive memory T cells. After quality filtering (see Methods) we analyzed in total 104,417 single cells from 6 unexposed and 14 COVID-19 patients. UMAP cluster analysis revealed five clusters with a distinct transcriptional profile (Figure 3A). These were assigned as T follicular-helper-like (Tfh-like, key marker genes IL21, POU2AF1). transitional memory (CD28, IL7R), central memory (CCR7, SELL), cytotoxic (IFNG, CSF2, PRF1, GNLY), type-I interferon response (MX1, OAS1) and cycling T cells (MKI67, CDK1) (Figure 3B). Similar clusters have recently been described in anti-viral T cells (Meckiff et al., 2020). However, especially Tfh-like, transitional and central memory T cells were related and important genes like IFNG, CSF2, IL21, IL2 and PDCD1 were expressed by many cells in all clusters although at different level (Figures 3B, Figure S3A). In addition, we observed three robust clusters, cytotoxic /Th1, type-I interferon, and cycling, which are indicative of cellular activation and an anti-viral type-I interferon response. These results confirm our cytometric analysis pointing to a highly activated Th1 and Tfh-like phenotype of SARS-CoV-2 specific T cells in COVID-19. However, similar clusters were also identified in SARS-CoV-2 reactive memory T cells from unexposed individuals and we were not able to clearly separate unexposed donors from COVID-19 patients or between patients with different disease severity only based on qualitative differences of the reactive T cells (Figure 3C, Figure S3B). There was a tendency that clusters indicative of acute activation, such as cycling and type-I interferon were relatively enriched in COVID-19 and Tfh cells were more abundant in mild COVID19 (Figure 3C). Taken together, the cytometric and single cell sequencing data confirm that COVID-19 patients generate a strong pro-inflammatory Th1/cytotoxic-like and Tfh-like response against SARS-

CoV-2 spike, membrane, and Ncap proteins. Interestingly though, the differences between the

patients groups and healthy controls were mainly quantitative, rather than qualitative. This suggests that these cell types are not unique to COVID-19 but may represent a common cellular phenotype of anti-viral T cells, which are already present in pre-existing SARS-CoV-2-reactive memory T cells from healthy unexposed donors.

202

203

204

205

206 207

208209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

Low avidity SARS-CoV-2-reactive memory T cells increase with age in unexposed donors

Recent studies have demonstrated pre-existing T cell immunity against SARS-CoV-2 presumably against common cold viruses in 20-50% of unexposed donors (Braun et al., 2020; Grifoni et al., 2020; Le Bert et al., 2020; Mateus et al., 2020; Meckiff et al., 2020; Sekine et al., 2020; Weiskopf et al., 2020). However, the antigen specificity as well as the clinical relevance of this cross-reactivity remains unknown (Sette and Crotty, 2020) although some crossreactivity against homologous CCCoV epitopes has been found (Braun et al., 2020; Mateus et al., 2020). As shown in Figure 1, by sensitive enrichment of reactive T cells we detected low frequencies of cross-reactive T cells against different SARS-CoV-2 proteins in 100% of unexposed donors. To further characterize these pre-existing SARS-CoV-2-reactive T cells, we determined the proportion of memory versus naïve cells. Remarkably, a substantial fraction of SARS-CoV-2-reactive cells from unexposed donors but not COVID-19 patients displayed a naïve phenotype, as evidenced by high expression of CD45RA and CCR7 and lack of effector cytokine expression (Figure 4A, B; Figure 2F). The proportion of memory cells was highly variable between different donors (range 25-95%) (Figure 4B). It has further been speculated that this pre-existing immunity may improve protection especially in young patients and children due to frequent infections with common cold corona viruses (Braun et al., 2020). However, we detected no correlation of pre-existing T cell frequency with donor age (Figure 4C). Rather and in sharp contrast to the "pre-immune" hypothesis, the frequency (Figure 4D) and the proportion (Figure 4E) of SARS-CoV-2 cross-reactive memory cells of unexposed individuals positively correlated with the proportion of memory cells within the total CD4+ population that is associated to the immunological age. A similar pattern was observed for CMV-reactive T cells from CMV sero-negative versus sero-positive donors (Figure 4E), as well as T cells reactive against the neoantigen keyhole limpet hemocyanin (KLH) (Figure S4). These data argue against induction of the pre-existing SARS-CoV-2 memory cells by a specific cross-reactive antigen, but rather for arbitrary stochastic selection from a large memory repertoire in adult humans. In support of this, SARS-CoV-2-reactive memory T cells expanded from unexposed individuals displayed a 1-2 log lower functional avidity compared to COVID-19 patients, which was in the same range as CMV-reactive T cells (Figure 4F, G). Taken together, pre-existing SARS-CoV-2 cross-reactive memory T cells in unexposed donors are

common in humans and increase with the immunological age but do not display features of a protective cross-reactive T cell population.

Robust memory T cell response to common cold corona viruses (CCCoVs)

239240

241242

243

244

245

246

247

248

249250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267268

269

270

271

272

273

274

275

Our data do not exclude the possibility that in some donors protective pre-existing immunity may exist, for example due to infections with related common cold corona viruses (CCCoVs). Since data on the prevalence of CCCoV-specific T cell memory are lacking, we next analysed the response against spike proteins from the CCCoV strains 229E, OC43, HKU1 and NL63. Strikingly, robust memory T cell responses were readily detected in all donors with frequencies ranging between 1 in 10³-10⁴ (Figure 5A, B), which is in a similar range like against Influenza A (Figure 1C), but up to 10-fold higher than SARS-CoV-2 spike-reactive T cells (Figure 5B). CCCoV responses displayed a memory phenotype (Figure 5C, D), independent of immunological age (Figure S5A), and high functional avidity (Figure 5E) in accordance with an in vivo induction upon viral infection. Of note, expanded CCCoV-specific T cells from healthy donors showed only marginal cross-reactivity against SARS-CoV-2 spike protein and vice versa (Figure 5F, G). Furthermore, while the frequencies of reactive memory T cells between the different CCCoVs showed strong linear correlation as an indicator of cross-recognition, there was only a weak correlation between SARS-CoV-2 memory T cells and individual CCCoV strains (Figure 5H), which was in fact similar to other non-related common viral antigens (Figure S5B). To further analyse the potential relevance of pre-existing immunity to the anti-SARS-CoV-2 immune reponse, we re-stimulated expanded SARS-CoV-2-specific T cell lines from COVID-19 patients and unexposed donors (Figure 5I, J). Only minimal and highly variable cross-reactivity against CCCoV strains, but also against CMV or Influenza A were detected in COVID-19 patients, as well as in expanded cells from unexposed individuals, adding up to maximally 5% of the total response in individual donors (Figure 51). Taken together these data clearly argue against a strong protective effect of pre-existing immunity in general and specifically against a major protective contribution of CCCoVs to the T cell response against SARS-CoV-2 in unexposed donors, as well as in COVID-19 patients.

Increased, but unfocussed and low affinity CD4+ T cell response against SARS-CoV-2 in severe disease

Although we essentially excluded a general protective effect of pre-existing immunity we demonstrated that cross-reactive memory T cells against SARS-CoV-2 antigens are common in humans, increase with the immunological age and display rather low functional avidity. So far, the consequences of this stochastic pre-existing memory are unclear. Since elderly suffer more frequent from severe disease, we next compared the response of patients with mild *versus* severe disease. Classification was based on WHO criteria, whereby WHO groups 3-5

276

277

278

279

280

281

282

283

284

285

286

287

288

289 290

291

292

293

294

295

296

297

298

299

300

301 302

303

304

305

306

307

(moderate) and 6-7 (severe) were combined to increase statistical power (see Table S1). Interestingly, frequencies of reactive T cells against the single and pooled SARS-CoV-2 proteins, but not against Influenza A antigens positively correlated with disease severity (Figure 6A). This was not due to an age bias in severe disease as shown for a selected group of donors in the age range of 50-65 years (Figure 6B, C). Instead, we observed a clearly increased immunological age of hospitalized versus non-hospitalized patients within the same age group (Figure 6D). To test whether the immunological age-related cross-reactive memory may impact on COVID-19 severity, we also compared TCR avidities and clonalities of SARS-CoV-2-reactive T cells from hospitalized versus non-hospitalized patients. Strikingly, SARS-CoV-2 reactive T cells from hospitalized patients displayed significantly lower functional avidity compared to nonhospitalized patients (Figure 6E-G). In line with this, SARS-CoV-2-specific T cells from hospitalized COVID-19 patients displayed a trend towards a more diverse TCR repertoire (Figure 6H) and reduced clonal expansions, as indicated by the lower Gini coefficient, as a measure of the eveness of a population (Figure 6I). However, this was not significant due to one outlier (grey dot in Figure 6G-I, see below). Thus despite strongly increased T cell frequencies in severe COVID-19 (Figure 6A), this increase did not result from an expansion of individual clones, but instead reflected a broad polyclonal response. We next analyzed the distribution of the most clonally expanded TCRs per patient within the different clusters of the single-cell RNA sequencing analysis. Interestingly, we observed a tendency that in mild disease the most expanded clones were mainly restricted to the cytotoxic cluster, whereas in more severe disease, they were scattered over several clusters (Figure 6J, K). One severe COVID-19 patient (grey dot in Figure 6G-I) did not fit into this scheme and also showed a high clonality strongly focused to the cytotoxic cluster (Figure 6K, lower right). Interestingly this patient suffered from a CMV reactivation, which may account for expansion of cross-reactive clones. Still the cells from this donor were of low avidity for SARS-CoV-2 antigens (Figure 6G, grey dot) confirming the robustness of the avidity data. In summary our data suggest that severe COVID-19 disease is characterized by a strong but rather unfocused virus-specific CD4+ T cell response involving a broad polyclonal repertoire of rather low avidity T cells. Such unfocused, low avidity response may in fact result from preferential recruitment of a broad pre-existing memory repertoire preferentially present in the elderly.

Discussion

308

309

310311

312

313

314

315

316317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342343

344345

Defining the parameters contributing to the high clinical variability of COVID-19 is essential to predict disease outcome and develop effective therapeutic and vaccination strategies. Here we provide two key observations, suggesting a negative impact of pre-existing T cell memory which may explain the age-bias of COVID-19 severity: First, we show that all COVID-19 patients generate strong pro-inflammatory T cells responses, that increased with disease severity. Unexpectedly, severe disease is associated with lower functional avidity and TCR clonality. Second, we identify SARS-CoV-2 "pre-existing" T cell memory as a common feature related to the immunological age of an individual, which recapitulates the low functional avidity found in severe COVID-19 and suggests a causative relation. Our cytometric and single-cell RNA sequencing characterization of SARS-CoV-2 memory T cells confirmed previous results showing common characteristics of an anti-viral T cell response but did not identify clear-cut differences between severe and mild disease. Surprisingly, similar cell clusters were present in SARS-CoV-2-specific memory T cells from unexposed controls. Thus quantitative differences rather than unique functionality profiles develop in COVID-19. Indeed, all COVID-19 patients develop strong, pro-inflammatory Th1like CD4+ T cell responses directed against the three main proteins spike, membrane and Ncap, as shown before for convalescent patients (Grifoni et al., 2020), Interestingly, despite the reported T cell lymphopenia in severe disease, SARS-CoV-2-specific T cell frequencies increased with disease severity (Anft et al., 2020; Peng et al., 2020). Compared to other common viruses SARS-CoV-2-specific T cells showed signs of recent activation, such as CD38, Ki-67 and PD1, as well as CD154 and high IL-21 production indicative of B cell helper function. Also the slightly reduced expression of cytokines like IFN- γ , TNF- α and IL-2 compared to other anti-viral responses may be related to the recent activation. Thus the T cell response phenotype per se does not explain disease severity but will require detailed longitudinal analysis in the future. The preferential formation of a highly focused clonal T cell population within the cytotoxic cluster in mild COVID-19 suggests their potential protective function, which may deserve further detailled analysis, including their peptide specificities. We also characterized pre-existing memory as one factor for quantitative differences in the T cell response in mild versus severe disease. The observation that SARS-CoV-2 specific T cells were found in a subset of unexposed donors (Braun et al., 2020; Grifoni et al., 2020; Le Bert et al., 2020; Mateus et al., 2020; Meckiff et al., 2020; Sekine et al., 2020; Weiskopf et al., 2020), has initially fueled the hypothesis of protective pre-existing immunity, for example induced by related CCCoVs preferentially in young people (Braun et al., 2020; Mateus et al., 2020). Such heterologous immunity between related pathogens has been previously demonstrated mainly in infection models (Welsh et al., 2010) but may also modulate human immune responses (Bacher et al., 2019; Gras et al., 2010; Hayward et al., 2015; Koutsakos et al., 2019; Sridhar

346

347

348

349350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

et al., 2013). So far, cross-reactivity of SARS-CoV-2 reactive T cells was poorly characterized and their functional impact remained unknown. In line with our results, a weak correlation between CCCoV and SARS-CoV-2 T cell responses in unexposed donors has been identified and cross-reactivity to CCCoV was observed in SARS-CoV-2-specific T cell lines directed against the most homologous part of spike proteins (Braun et al., 2020) or selected homologous peptides (Mateus et al., 2020). Our more detailled analysis of cross-reactivity in healthy and COVID-19 patients argues against a major role of CCCoVs: Pre-existing memory T cells were detected in all unexposed donors and their frequencies correlated with the immunological age but not with CCCoV-specific memory. Furthermore pre-existing memory cells displayed low functional avidity and were less focused on the dominant COVID-19 targets spike, membrane and Ncap protein (Figure 1D) (Grifoni et al., 2020; Le Bert et al., 2020). Most importantly, CCCoV cross-reactivity both within SARS-CoV-2-specific T cells from COVID-19 patients, as well as unexposed donors, was marginal despite the ubiquitous presence of a strong CCCoV-specific memory T cell response in all tested donors. Interestingly, also Mateus et al. found that SARS-CoV-2-specific, but not cross-reactive T cells against the homologous CCCoV peptides increased in COVID-19 patients (Mateus et al., 2020), supporting our finding. Thus CCCoV-specific T cell memory is common in the human population but seems to have minimal impact on SARS-CoV-2-specific immunity. It is important to mention that our demonstration of strong T cell memory against all four CCCoV strains in all tested donors may be an encouraging sign that protective cellular immunity against SARS-CoV-2 might also persist longterm, even if antibody responses are transient (Seow, 2020). An even more important role of pre-existing memory in COVID-19 and for human immunity in general is emerging from our analysis. In contrast to previous reports we find memory T cells against SARS-CoV-2 in all tested unexposed donors. This probably reflects the high sensitivity and specificity of the ARTE assay. In fact, lack of magnetic pre-selection, prolonged stimulation times and the use of frozen PBMC may limit sensitivity and specificity (Bacher and Scheffold, 2013, 2015). However, this pre-existing memory does not represent classical heterologous immunity between related pathogens. Instead, pre-existing SARS-CoV-2 memory has features of an unbiased, stochastic cross-reactivity within a large TCR repertoire similar as observed against other neoantigens. This is supported by its ubiquitous presence and broad protein specificity (Figure 1D) as well as its strong positive correlation with total CD4+ memory (Figure 4D, E). Especially the low functional avidity argues against *in vivo* affinity selection (Figure 4G) (Bacher et al., 2016). Memory T cells against neo-antigens are commonly detected in humans (Bacher et al., 2013; Campion et al., 2014; Kwok et al., 2012; Su et al., 2013). This can be explained by the known TCR-intrinsic cross-reactivity against related and even unrelated but structurally similar peptides (Birnbaum et al., 2014; Sewell, 2012). Thus a highly diverse

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401 402

memory pool, which accumulates in humans over lifetime contains TCRs specific for neoantigens similar to the naïve T cell pool. The impact of pre-existing memory on T cell responses against neoantigens in humans is poorly understood. However, its correlation with the immunological age suggests increasing impact in the elderly (Lanzer et al., 2018; Lanzer et al., 2014; Woodland and Blackman, 2006) and it is tempting to speculate that this may contribute to the increased risk for severe COVID-19 in the aged population. Since memory T cells have a lower activation threshold, a large number of suboptimal low avidity memory cells may compete and prevent naïve T cell activation and high affinity selection (Lanzer et al., 2018). Indeed the size of the naïve T cell pool has been shown to correspond to vaccination success (Kwok et al., 2012; Schulz et al., 2015; Woodland and Blackman, 2006). Thus we hypothesize that pre-existing memory may contribute to the reduced avidity and higher diversity of TCRs in severe COVID-19. Such a polyclonal and low avidity T cell response may also be less susceptible to intrinsic negative control mechansims, which may explain the increased SARS-CoV-2-reactive T cell response. Pre-existing memory indeed represents a general mechanism of immune-modulation towards neo-antigens, especially in the elderly (Woodland and Blackman, 2006). Provided the great heterogeneity within the human population with regard to antigen exposure and MHC composition, we expect in fact highly variable and context-dependent effects of pre-existing memory from protective to harmful. Therefore the impact of pre-existing memory on neoantigen exposure, including sensitizing antigens, infections or vaccinations, as well as for

autoantigens has to be carefully evaluated in future studies.

Acknowledgments

- We thank Chiara Romagnani and Ulf Klein for critical reading of the manuscript, the flow
- 405 cytometry facility Cyto Kiel, especially Esther Schiminsky and the Competence Centre for
- 406 Genomic Analysis (CCGA) Kiel, especially Janina Fuß, Sören Franzesnburg, Yewgenia
- 407 Dolshanskaya, Catharina von der Lancken, Melanie Vollstedt and Melanie Schlapkohl for
- 408 support with cell sorting and single cell sequencing; the Clinical Trial Unit 2 of the University
- 409 Hospital of Cologne for help with recruiting study participants and technical assistance.
- This research was supported by the German Research Foundation (DFG) under Germany's
- 412 Excellence Strategy EXC 2167-390884018 Precision Medicine in Chronic Inflammation (to
- 413 P.B., A.F., A.S.); RU5042 miTarget to P.B., A.F.; DFG grant n. 4096610003 to E.R; FL and
- DE were supported by the E-Rare Joint Transnational research support (ERA-Net, LE3064/2-
- 415 1).

416 417

418

423 424

425

403

410

Author contributions

- 419 Conceptualization: P.B., A.S.; Investigation: P.B., E.R., G.R.M., C.S.; Formal analysis: P.B.,
- 420 E.R., D.E. P.K.; Resources: J.D., I.S., I.W., F.E., Y.K., M.J.G.T., C.C., F.T., P.R., R.M., K.P.W.,
- 421 F.L., J.R., M.K., O.A.C., P.K., A.F.; Funding acquisition: P.B., A.S.; All authors provided
- 422 discussion, participated in revising the manuscript, and agreed to the final version.

Disclosure of potential conflicts of interest

- 426 P.B., A.S. are consultants of Miltenyi Biotec, who own IP rights concerning parts of the ARTE
- 427 technology.
- 428 P.K. has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch
- 429 Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in
- 430 Aging-Associated Diseases, University of Cologne, Cologne, Germany, and received lecture
- 431 honoraria from or is advisor to Akademie für Infektionsmedizin e.V., Astellas Pharma, the
- 432 European Confederation of Medical Mycology, Gilead Sciences, GPR Academy
- 433 Ruesselsheim, MSD Sharp & Dohme GmbH, Noxxon N.V., and University Hospital, LMU
- 434 Munich outside the submitted work.
- 435 O.A.C. is supported by the German Federal Ministry of Research and Education, is funded by
- 436 the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under
- 437 Germany's Excellence Strategy CECAD, EXC 2030 390661388 and has received research
- 438 grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra, Amplyx,
- 439 Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, IQVIA,
- Janssen, Matinas, Medicines Company, MedPace, Melinta, Menarini, Merck/MSD, Mylan,

Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi.

FL is supported by German Ministry of Education and Research (01GM1908A) and E-Rare Joint Transnational research support (ERA-Net, LE3064/2-1) and discloses speaker honoraria from Grifols, Teva, Biogen, Bayer, Roche, Novartis, Fresenius, travel funding from Merck, Grifols and Bayer and serving on advisory boards for Roche, Biogen and Alexion.

441442

443

444 445

References

- 448 Anft, M., Paniskaki, K., Blazquez-Navarro, A., Atila, A., Doevelaar, N., Seibert, F., Hoelzer, B.,
- Skrzypczyk, S., Kohut, E., Kurek, J., et al. (2020). COVID-19 progression is potentially driven
- 450 by T cell immunopathogenesis. medRxiv.
- 451 Bacher, P., Heinrich, F., Stervbo, U., Nienen, M., Vahldieck, M., Iwert, C., Vogt, K., Kollet, J.,
- Babel, N., Sawitzki, B., et al. (2016). Regulatory T Cell Specificity Directs Tolerance versus
- 453 Allergy against Aeroantigens in Humans. Cell 167, 1067-1078 e1016.
- Bacher, P., Hohnstein, T., Beerbaum, E., Rocker, M., Blango, M.G., Kaufmann, S., Rohmel,
- J., Eschenhagen, P., Grehn, C., Seidel, K., et al. (2019). Human Anti-fungal Th17 Immunity
- and Pathology Rely on Cross-Reactivity against Candida albicans. Cell 176, 1340-1355 e1315.
- 457 Bacher, P., and Scheffold, A. (2013). Flow-cytometric analysis of rare antigen-specific T cells.
- 458 Cytometry A 83, 692-701.
- Bacher, P., and Scheffold, A. (2015). New technologies for monitoring human antigen-specific
- 460 T cells and regulatory T cells by flow-cytometry. Curr Opin Pharmacol 23, 17-24.
- Bacher, P., Schink, C., Teutschbein, J., Kniemeyer, O., Assenmacher, M., Brakhage, A.A., and
- Scheffold, A. (2013). Antigen-reactive T cell enrichment for direct, high-resolution analysis of
- the human naive and memory Th cell repertoire. J Immunol 190, 3967-3976.
- Birnbaum, M.E., Mendoza, J.L., Sethi, D.K., Dong, S., Glanville, J., Dobbins, J., Ozkan, E.,
- Davis, M.M., Wucherpfennig, K.W., and Garcia, K.C. (2014). Deconstructing the peptide-MHC
- specificity of T cell recognition. Cell *157*, 1073-1087.
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S.,
- Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020). SARS-CoV-2-reactive T cells in healthy
- donors and patients with COVID-19. Nature.
- Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell
- transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36,
- 472 411-420.
- 473 Campion, S.L., Brodie, T.M., Fischer, W., Korber, B.T., Rossetti, A., Goonetilleke, N.,
- 474 McMichael, A.J., and Sallusto, F. (2014). Proteome-wide analysis of HIV-specific naive and
- 475 memory CD4(+) T cells in unexposed blood donors. J Exp Med 211, 1273-1280.
- 476 Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et
- 477 al. (2020). Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus
- 478 Disease 2019 (COVID-19). Front Immunol 11, 827.
- 479 Finak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A.K., Slichter, C.K., Miller,
- 480 H.W., McElrath, M.J., Prlic, M., et al. (2015). MAST: a flexible statistical framework for
- 481 assessing transcriptional changes and characterizing heterogeneity in single-cell RNA
- 482 sequencing data. Genome Biol 16, 278.
- 483 Gras, S., Kedzierski, L., Valkenburg, S.A., Laurie, K., Liu, Y.C., Denholm, J.T., Richards, M.J.,
- 484 Rimmelzwaan, G.F., Kelso, A., Doherty, P.C., et al. (2010). Cross-reactive CD8+ T-cell
- immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl
- 486 Acad Sci U S A 107, 12599-12604.
- 487 Greiling, T.M., Dehner, C., Chen, X., Hughes, K., Iniguez, A.J., Boccitto, M., Ruiz, D.Z.,
- Renfroe, S.C., Vieira, S.M., Ruff, W.E., et al. (2018). Commensal orthologs of the human
- autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med 10.
- 490 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
- 491 S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T Cell Responses to
- 492 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
- 493 Cell 181, 1489-1501 e1415.
- Hayward, A.C., Wang, L., Goonetilleke, N., Fragaszy, E.B., Bermingham, A., Copas, A.,
- 495 Dukes, O., Millett, E.R., Nazareth, I., Nguyen-Van-Tam, J.S., et al. (2015). Natural T Cell-
- 496 mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch
- 497 Cohort Study. Am J Respir Crit Care Med 191, 1422-1431.
- 498 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al.
- 499 (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
- 500 Lancet 395, 497-506.

- Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner,
- M., Loh, P.R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-
- 503 cell data with Harmony. Nat Methods 16, 1289-1296.
- Koutsakos, M., Illing, P.T., Nguyen, T.H.O., Mifsud, N.A., Crawford, J.C., Rizzetto, S., Eltahla,
- A.A., Clemens, E.B., Sant, S., Chua, B.Y., et al. (2019). Human CD8(+) T cell cross-reactivity
- across influenza A, B and C viruses. Nat Immunol 20, 613-625.
- 507 Kwok, W.W., Tan, V., Gillette, L., Littell, C.T., Soltis, M.A., LaFond, R.B., Yang, J., James,
- 508 E.A., and DeLong, J.H. (2012). Frequency of epitope-specific naive CD4(+) T cells correlates
- with immunodominance in the human memory repertoire. J Immunol 188, 2537-2544.
- Lanzer, K.G., Cookenham, T., Reiley, W.W., and Blackman, M.A. (2018). Virtual memory cells
- 511 make a major contribution to the response of aged influenza-naive mice to influenza virus
- 512 infection. Immun Ageing *15*, 17.
- Lanzer, K.G., Johnson, L.L., Woodland, D.L., and Blackman, M.A. (2014). Impact of ageing on
- the response and repertoire of influenza virus-specific CD4 T cells. Immun Ageing 11, 9.
- Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin,
- 516 M., Tan, N., Linster, M., et al. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-
- 517 19 and SARS, and uninfected controls. Nature.
- 518 Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S.I., Dan, J.M., Burger, Z.C., Rawlings,
- 519 S.A., Smith, D.M., Phillips, E., et al. (2020). Selective and cross-reactive SARS-CoV-2 T cell
- 520 epitopes in unexposed humans. Science.
- Meckiff, B.J., Ramirez-Suastegui, C., Fajardo, V., Chee, S.J., Kusnadi, A., Simon, H., Grifoni,
- A., Pelosi, E., Weiskopf, D., Sette, A., et al. (2020). Single-cell transcriptomic analysis of
- 523 SARS-CoV-2 reactive CD4 (+) T cells. bioRxiv.
- Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T.,
- Supasa, P., Liu, C., et al. (2020). Broad and strong memory CD4 (+) and CD8 (+) T cells
- 526 induced by SARS-CoV-2 in UK convalescent COVID-19 patients. bioRxiv.
- 527 Schulz, A.R., Malzer, J.N., Domingo, C., Jurchott, K., Grutzkau, A., Babel, N., Nienen, M.,
- Jelinek, T., Niedrig, M., and Thiel, A. (2015). Low Thymic Activity and Dendritic Cell Numbers
- 529 Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans. J
- 530 Immunol 195, 4699-4711.
- 531 Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.B., Olsson, A.,
- 532 Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020). Robust T cell
- immunity in convalescent individuals with asymptomatic or mild COVID-19. bioRxiv.
- 534 Seow, J. (2020). Longitudinal evaluation and decline of antibody responses in SARS-CoV-2
- 535 infection. medRxiv.
- 536 Sette, A., and Crotty, S. (2020). Pre-existing immunity to SARS-CoV-2: the knowns and
- 537 unknowns. Nat Rev Immunol.
- 538 Sewell, A.K. (2012). Why must T cells be cross-reactive? Nat Rev Immunol 12, 669-677.
- 539 Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T.,
- Barclay, W., Deeks, J.J., and Lalvani, A. (2013). Cellular immune correlates of protection
- against symptomatic pandemic influenza. Nat Med *19*, 1305-1312.
- 542 Su, L.F., Kidd, B.A., Han, A., Kotzin, J.J., and Davis, M.M. (2013). Virus-specific CD4(+)
- 543 memory-phenotype T cells are abundant in unexposed adults. Immunity 38, 373-383.
- 544 Tan, L., Wang, Q., Zhang, D., Ding, J., Huang, Q., Tang, Y.Q., Wang, Q., and Miao, H. (2020).
- 545 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal
- 546 Transduct Target Ther 5, 33.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong,
- 548 Y., et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
- 549 Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
- Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
- 551 Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., et al. (2020). Phenotype
- and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory
- 553 distress syndrome. Sci Immunol 5.
- Welsh, R.M., Che, J.W., Brehm, M.A., and Selin, L.K. (2010). Heterologous immunity between
- 555 viruses. Immunol Rev 235, 244-266.

- Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivison,
- 557 G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral
- immune response in patients with severe COVID-19. Nat Med 26, 1070-1076.
- Woodland, D.L., and Blackman, M.A. (2006). Immunity and age: living in the past? Trends Immunol 27, 303-307.
- 561 Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al.
- 562 (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in
- Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med *8*, 475-481.
- Zheng, H.Y., Zhang, M., Yang, C.X., Zhang, N., Wang, X.C., Yang, X.P., Dong, X.Q., and
- Zheng, Y.T. (2020). Elevated exhaustion levels and reduced functional diversity of T cells in
- 567 peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol *17*,
- 568 541-543.

Figure Legends

570

571 572

576

577

578

587 588 589

590

609 610 611

612

613

614

615 616

623 624 625

Figure 1. Identification of immunogenic SARS-CoV-2 proteins

- (A) Frequencies of reactive CD154+CD45RA- memory CD4+ T cells (Tmem) against individual SARS-CoV-2 proteins in unexposed donors (n=9) and COVID-19 patients (n=11; non-hospitalized n=8; hospitalized n=3).
 - (B) Representative dot plot examples for *ex vivo* detection of SARS-CoV-2-reactive CD4+ T cells by ARTE. Absolute cell counts after magnetic CD154+ enrichment from 1x10e7 PBMCs are indicated.
- 579 (C) Frequencies of SARS-CoV-2-reactive Tmem against individual or pooled spike, 580 membrane, Ncap proteins or a pool of Influenza A proteins (containing HA, MP1, MP2, NP and 581 NA). Unexposed donors (n=50), COVID-19 patients (n=49).
- 582 (D) Proportion of SARS-CoV-2 proteins recognized by CD4+ T cells in unexposed donors (n=9) and COVID-19 patients (n=11).
- Each symbol in (A, C) represents one donor. (A) Box-and-whisker plots display quartiles and range. (C) Horizontal lines indicate geometric mean. Statistical differences: (C) Two-tailed Mann-Whitney test.

Figure 2. Inflammatory SARS-CoV-2-specific CD4+ T cell responses in COVID-19 patients

- 591 (A) Ex vivo Ki-67 and CD38 expression of SARS-CoV-2 pool-reactive CD154+ Tmem. Unexposed donors (n=50), COVID-19 patients (n=49).
- (B) Ex vivo Ki-67 and CD38 staining of SARS-CoV-2 pool- or Influenza A-reactive CD154+ Tmem from COVID-19 patients at different time points after disease onset. Percentage of Ki-67+ and/ or CD38+ cells within CD154+ Tmem are indicated.
- (C) Spearman correlation of Ki-67 and CD38 expression or frequencies of SARS-CoV-2 poolreactive CD154+ Tmem and days since disease onset in COVID-19 patients (n=49).
- (D) Ex vivo cytokine and phenotype staining of SARS-CoV-2 pool-reactive CD154+ Tmem from a COVID-19 patient. Percentage of marker positive cells within CD154+ Tmem are indicated.
- (E) Ex vivo cytokine production and phenotype of SARS-CoV-2 pool-reactive cells. Upper row: within CD154+ Tmem and lower row: within total CD4+ T cells. Unexposed donors (n=50; IL-21 n=31), COVID-19 patients (n=49; IL-21 n=26).
- (F) Heatmap depicting *ex vivo* cytokine production of virus-reactive memory T cells (n=26-50). Cytokine production within CD154+ Tmem was measured by flow cytometry and mean values
- were Z score normalized for each cytokine.
- Each symbol in (A, C, E) represents one donor, horizontal lines indicate (A) geometric mean, (E) mean. Statistical differences: (A, E) Two-tailed Mann-Whitney test.

Figure 3. Single cell RNA sequencing of SARS-CoV-2-reactive CD4+ T cells

- (A) Single cell gene expression of FACS purified *ex vivo* isolated CD154+ memory T cells following stimulation with pooled SARS-CoV-2 spike, membrane and Ncap proteins from unexposed donors (n=6) and COVID-19 patients (n=14). UMAP visualization of the subset composition of SARS-CoV-2 reactive CD4+ T cells colored by functional gene expression clusters.
- (B) Dot plot visualization showing the expression of selected marker genes in each SARS-CoV-2 T cell cluster. Colors represent the Z-score normalized expression levels and size indicates the proportion of cells expressing the respective genes.
- 620 (C) Proportion of cells falling within each cluster for the individual donors (unexposed donors n=6; non-hospitalized COVID-19 patients n=6; hospitalized COVID-19 patients (n=8).
- 622 Each symbol in (C) represents one donor, horizontal lines indicate mean.

Figure 4. SARS-CoV-2 reactive CD4+ T cells in healthy donors

- 626 (A) CD45RA and CCR7 staining of SARS-CoV-2- or Influenza A-reactive CD154+ cells in unexposed donors or COVID-19 patients. Percentage of marker positive cells within CD154+ is indicated.
- 629 (B) Proportion of memory cells within SARS-CoV-2 reactive cells in unexposed donors (n=50) or COVID-19 patients (n=49).
- 631 (C, D) Spearman correlation between the frequencies of SARS-CoV-2 pool-reactive T cells in 632 unexposed donors and (C) the age of donors or (D) the proportion of memory cells within the 633 total CD4+ population, corresponding to the immunological age.

- (E) Pearson correlation between the proportion of memory cells within the antigen-specific T cells (y-axis) and the proportion of memory cells within the total CD4+ population (x-axis; immunological age) is shown for exposed and unexposed donors for SARS-CoV-2 and CMV. (F, G) SARS-CoV-2 pool-reactive CD154+ Tmem from unexposed donors and COVID-19 patients were FACS purified, expanded and re-stimulated with decreasing antigen concentration in the presence of autologous antigen-presenting cells. (F) CD154 or TNF-α expression for the indicated concentration per peptide. (G) EC50 values were calculated from dose-response curves. Left: SARS-CoV-2 reactive cells from unexposed donors n=8, COVID-19 patients n=19; right: CMV-reactive cells n=5 or SARS-CoV-2 reactive from COVID-19 patients (n=19).
- Each symbol in (B, C, D, E, G) represents one donor, horizontal lines indicate (B) mean. (G) Box-and-whisker plots display quartiles and range. Statistical differences: (G) Two-tailed Mann-Whitney test.

Figure 5. Human CD4+ T cell response against common cold viruses (CCCoVs)

- (A) Ex vivo detection of reactive CD4+ T cells against CCCoV spike proteins by ARTE. Absolute cell counts after magnetic CD154+ enrichment from 1x10e7 PBMCs are indicated.
- (B) Summary of CCCoV-reactive Tmem frequencies in healthy donors (n=34).
- 653 (C) CD45RA and CCR7 staining of CCCoV-reactive CD154+ cells in healthy donors. 654 Percentage of marker positive cells within CD154+ is indicated.
- (D) Proportion of memory cells within CCCoV-reactive cells in healthy donors (n=34).
- (E-G) CD154+ Tmem reactive against a pool of the 229E, OC43, HKU1 and NL63 spike proteins or reactive against the SARS-CoV-2 spike, membrane and Ncap proteins were FACS purified, expanded and re-stimulated. (E) Cells were re-stimulated with decreasing antigen concentration. EC50 values were calculated from dose-response curves. (F) Reactivity of the expanded cell lines against CCCoV spike pool or SARS-CoV-2 spike protein, respectively (n=3-4). (G) Representative dot plots for re-stimulation. Percentage of CD154+TNFα+ cells within CD4+ is indicated.
- 663 (H) Spearman correlation between CD154+ Tmem frequencies reactive against different 664 CCCoVs or CCCoVs and SARS-CoV-2 spike (n=34).
 - (I, J) Expanded SARS-CoV-2 pool-reactive T cells from COVID-19 patients (n=19) or unexposed individuals (n=9) were re-stimulated with different antigens in presence of autologous antigen-presenting cells. (I) Signal:noise ratio of stimulated *versus* non-stimulated control. A detection limit (dashed line), was defined as signal:noise ratio \geq 3. (J) Dot plot examples for re-stimulation of a COVID-19 patient. Cells were gated on CD4+ T cells and percentages of CD154+TNF α + cells are indicated.
 - Each symbol in (B, D, E, F, H, I) represents one donor, horizontal lines indicate (A, B) mean, (I) geometric mean. (E-F) Box-and-whisker plots display quartiles and range. Statistical differences: (B, D) Friedman test with Dunn's post hoc test, (E) Two-tailed Mann-Whitney test.

Figure 6. Unfocussed T cell response in severe COVID-19

(A) Frequencies of SARS-CoV-2-reactive Tmem. The highest COVID-19 severity level during disease was assessed based on WHO criteria, whereby WHO groups 3-5 (moderate) and 6-7 (severe) were combined to increase statistical power (see Table S1). Unexposed donors n=50, Non-hospitalized n=26 (WHO 1-2), mild-moderate n=12 (WHO 3 n=2, WHO 4 n=6, WHO 5

- 681 n=4), severe n=11 (WHO 6 n=5, WHO 7 n=6); patients with active disease at the time point of sampling are indicated with a square.
- 683 (B) Age distribution within the different disease groups and controls and within the age-684 selected donors from 50-65 years.
- 685 (C) Frequencies of SARS-CoV-2-pool-reactive Tmem in age-selected donors.
- (D) Immunological age of the age-selected donors, indicated as the proportion of memory cells within the total CD4+ population.
- 688 (E-G) SARS-CoV-2 pool-reactive CD154+ Tmem were FACS purified, expanded and re-689 stimulated with decreasing antigen concentration in the presence of autologous antigen-690 presenting cells. (E) CD154 or TNF- α expression for the indicated concentration per peptide.
- (G) Dose-response curves of expanded T cell lines, restimulated with decreasing antigen concentrations. (F) EC50 values were calculated from dose-response curves. Non-hospitalized n=13, hospitalized n=6.
- 694 (H, I) T cell receptor (TCR) sequence analysis from single cell data of the top 50 expanded 695 clonotypes. (H) Simpson Index of TCR diversity. (I) Gini coefficient depicting the distribution of 696 TCR sequences (0 is total equality, i.e. all clones have the same proportion, 1 total inequality, 697 i.e. a population dominated by a single clone). Non-hospitalized n=6, hospitalized n=8.
- (J) Representative distribution of the top 3 expanded TCR clonotypes projected to the UMAP analysis for one exemplary non-hospitalized and one hospitalized COVID-19 patient.
- 700 (K) Proportional distribution of the top 3 expanded clonotypes on the different Seurat clusters for each analyzed patient (non-hospitalized n=6; hospitalized n=8).
- Each symbol in (A-D, G-I) represents one donor, horizontal lines indicate (A-D) mean. (G-I)
 Box-and-whisker plots display quartiles and range. Statistical differences: (A) Kruskal-Wallis
 test with Dunn's post hoc test, significant differences are indicated. (G-I) Two-tailed MannWhitney test.

Figure S1. Detection of SARS-CoV-2 reactive CD4+ T cells by ARTE

- (A) *Ex vivo* detection of SARS-CoV-2 pool-reactive CD4+ T cells by ARTE. Percentage within CD4+ T cells and absolute cell counts before and after magnetic CD154+ enrichment from 1×10e7 PBMCs are indicated.
- (B and C) Re-stimulation of FACS purified, expanded SARS-CoV-2 pool-reactive CD154+ T cells with the SARS-CoV-2 pool or Tetanus as control antigen. (B) Percentage of CD154+TNF α + cells within CD4+ is indicated. (C) Statistical summary, each symbol represents one donor. Box-and-whisker plots display quartiles and range. Unexposed donors (n=9), COVID-19 patients (n=19).

Figure S2. Pattern of SARS-CoV-2 reactive CD4+ T cells compared to other anti-viral responses.

- (A) Spearman correlation of cytokine and phenotypic marker expression of SARS-CoV-2 pool-reactive CD154+ Tmem and days since disease onset.
- (B) Ex vivo cytokine production and phenotype of SARS-CoV-2-reactive cells of reconvalescent COVID-19 patients in comparison to other anti-viral responses in SARS-CoV-2 unexposed donors (n=26-50).
- Each symbol in (A, B) represents one donor.

706 707 708

709

710

711

712

713

714

715

716

717 718 719

720

721 722

723

724

725

726

727 728

729

Figure S3. Gene expression of SARS-CoV-2 reactive CD4+ T cell clusters

- Single cell transcriptomes of FACS purified *ex vivo* isolated CD154+ memory T cells following stimulation with pooled SARS-CoV-2 spike, membrane and Ncap proteins from unexposed donors (n=6) and COVID-19 patients (n=14).
- 733 (A) Heatmap depicting Z-score normalized expression levels of the top 10 differential expressed marker genes of each cluster and other selected genes.

(B) UMAP visualization of the subset composition of SARS-CoV-2 reactive CD4+ T cells colored by functional gene expression clusters for unexposed donors (n=6) and non-hospitalized (n=6), moderate (WHO 4-5; n=5) and severe (WHO 6-7; n=3) COVID-19 patients.

Figure S4. Proportion of neoantigen-specific memory T cells correlates with the immunological age.

Pearson correlation between the proportion of memory cells within the antigen-specific T cells (y-axis) and the proportion of memory cells within the total CD4+ population is shown for the neoantigen keyhole limpet hemocyanin (KLH).

Figure S5. Correlations of SARS-CoV-2-reactive T cells of unexposed donors with the response against other common viruses

- (A) Pearson correlation between the proportion of memory cells within the CCCoV spike-specific T cells (y-axis) and the proportion of memory cells within the total CD4+ population (x-axis, immunological age) in SARS-CoV2-unexposed donors.
- (B) Spearman correlation between CD154+ Tmem frequencies reactive against different CCCoVs or SARS-CoV-2 and Influenza A (H1N1), Cytomegalovirus (CMV), Epstein–Barr Virus (EBV), Adenovirus (AdV) or tetanus in unexposed donors.
- Each symbol in (A, B) represents one donor.

Figure S6. SARS-CoV-2-reactive T cell in age-selected donors.

(A) Frequencies of Tmem reactive aganst the indicated SARS-CoV-2 proteins in donors with an age range of 50-65. The highest COVID-19 severity level during disease was assessed based on WHO criteria, whereby WHO groups 3-5 (moderate) and 6-7 (severe) were combined to increase statistical power (see table S1). Unexposed donors n=14, Non-hospitalized n=7 (WHO 1-2), moderate n=7 (WHO 3 n=1, WHO 4 n=3, WHO 5 n=3), severe n=5 (WHO 6 n=2, WHO 7 n=3,). Each symbol in represents one donor, horizontal lines indicate mean.

Materials & Methods CONTACT FOR REAGENT AND RESOURCE SHARING Further information and requests for reagents may be directed to the corresponding author Petra Bacher (petra.bacher@ikmb.uni-kiel.de). EXPERIMENTAL MODEL AND SUBJECT DETAILS **COVID-19** patients and unexposed donors This study was approved by the Institutional Review board of the UKSH Kiel (Identifier D 474/20), the University Hospital Frankfurt (Identifier 11/17) and patients were enrolled in the protocol Coronavirus Disease 19 – BioMaSOTA - Genetic factors and longitudinal monitoring of the immune response in COVID-19 (Identifier of the University of Cologne Ethics Committee 20-1295) and Improving Diagnosis of Severe Infections of Immunocompromised Patients (Identifier of the University of Cologne Ethics Committee 08-160) and signed informed consents. Peripheral EDTA blood samples were collected between April and July 2020 from 49 COVID-19 patients and from 50 in-house volunteers as unexposed controls (Table S1). 44 of 49 COVID-19 patients were tested positive and for SARS-CoV-2 RNA. We included 5 mild cases of COVID-19 without positive SARS-CoV2 RNA test, but with positive detection of antibodies using a certified antibody test (Elecsys Anti-SARS-CoV-2, Roche Diagnostics GmbH, Mannheim, Germany) who had clinical symptoms suggestive of COVID-19 and a traceable contact person found positive. All, except three active COVID-19 patients who had a positive SARS-CoV-2 RNA test, were tested positive for SARS-CoV-2 antibodies (Elecsys Anti-SARS-CoV-2, Roche Diagnostics GmbH and/ or Anti-SARS-CoV-2 ELISA, Euroimmun, Lübeck, Germany). All healthy controls were tested negative for SARS-CoV-2 antibodies (Elecsys Anti-SARS-CoV-2, Roche Diagnostics GmbH). The highest COVID-19 severity was assessed based on WHO ordinal scale (https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis).

METHOD DETAILS

Antigens

765

766 767

768769

770

771772

773774

775

776

777

778

779

780

781

782

783 784

785

786

787

788

789

790

791

792

793

794

795796

797 798

799

800

Pools of lyophilized 15-mer peptides with 11-amino acid overlap, covering the complete protein sequence were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany): SARS-

- 801 CoV-2 Membrane, Ncap or JPT (Berlin, Germany): SARS-CoV-2 Spike N-term, Spike C-term,
- 802 AP3A, ORF9B, ORF10, NS6, NS7a, NS7b, NS8, VEMP, Y14.
- Peptide pools of control antigens Influenza A H1N1 (HA, MP1, MP2, NP and NA), CMV (pp65,
- 804 IE-1), EBV (EBNA1, BZLF1, LMP2A, LMP1), AdV (Hexon) were purchased from Miltenyi
- 805 Biotec and CCCoV Spike proteins (229E, OC43, HKU1, NL63) from JPT. Pools were
- 806 resuspended according to manufacturer's instructions and cells were stimulated at a
- 807 concentration of 0.5 µg/peptide/ml. Tetanus-toxoid was purchased from Statens Serum
- 808 Institute and used at a concentration of 10µg/ml.

Antigen-reactive T cell enrichment (ARTE)

- Peripheral blood mononuclear cells were freshly isolated from 20-50ml EDTA blood on the day
- of blood donation by density gradient centrifugation (Biocoll; Biochrom, Berlin, Germany).
- Antigen-reactive T cell enrichment (ARTE) was performed as previously described (Bacher et
- al., 2019; Bacher et al., 2016). In brief, 0.5-2×10e7 PBMCs were plated in RPMI-1640 medium
- 815 (GIBCO), supplemented with 5% (v/v) human AB-serum (Sigma Aldrich, Schnelldorf,
- Germany) at a cell density of 1×10e7 PBMCs / 2 cm² in cell culture plates and stimulated for
- 7 hr in presence of 1 μ g/ml CD40 and 1 μ g/ml CD28 pure antibody (both Miltenyi Biotec,
- 818 Bergisch Gladbach, Germany). 1 μg/ml Brefeldin A (Sigma Aldrich) was added for the last 2
- 819 hr.

827828

836 837

809 810

- 820 Cells were labeled with CD154-Biotin followed by anti-Biotin (CD154 MicroBead Kit, Miltenyi
- 821 Biotec) and magnetically enriched by two sequential MS columns (Miltenyi Biotec). Surface
- staining was performed on the first column, followed by fixation and intracellular staining on
- the second column. Frequencies of antigen-specific T cells were determined based on the cell
- 824 count of CD154+ T cells after enrichment, normalized to the total number of CD4+ T cells
- applied on the column. For each stimulation, CD154+ background cells enriched from the non-
- 826 stimulated control were subtracted.

Flow cytometry

- 829 Cells were stained in different combinations of fluorochrome-conjugated antibodies (see Key
- Resources Table). Viobility 405/520 Fixable Dye (Miltenyi Biotec) was used to exclude dead
- 831 cells. For intracellular staining cells were fixed and permeabilized with the Inside stain Kit
- 832 (Miltenyi Biotec). Data were acquired on a or LSR Fortessa (BD Bioscience, San Jose, CA,
- 833 USA). Screening of expanded T cell lines on 384-well plates was performed on a
- 834 MACSQuantX Analyzer (Miltenyi Biotec). FlowJo (Treestar, Ashland, OR, USA) software was
- used for analysis.

In vitro expansion and re-stimulation of antigen-reactive T cell lines

For expansion of antigen-specific T cell lines, PBMCs were stimulated for 6 hr, CD154+ cells were isolated by MACS and further purified by FACS sorting on a FACS Aria Fusion (BD Bioscience, San Jose, CA, USA) based on dual expression of CD154 and CD69. Purified CD154+ T cells were expanded in presence of 1:100 autologous antigen-loaded irradiated feeder cells in TexMACS medium (Miltenyi Biotec), supplemented with 5% (v/v) human ABserum (GemCell), 200 U/ml IL-2 (Proleukin; Novartis, Nürnberg, Germany), and 100 IU/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B (Antibiotic Antimycotic Solution, Sigma Aldrich) at a density of 2.5×106 cells/cm². During expansion for 2-3 weeks, medium was replenished and cells were split as needed. For re-stimulation, fastDCs were generated from autologous CD14+ MACS isolated monocytes (CD14 MicroBeads; Miltenyi Biotec) by cultivation in X-Vivo™15 medium (BioWhittaker/Lonza), supplemented with 1000 IU/ml GM-CSF and 400 IU/ml IL-4 (both Miltenyi Biotec). Before re-stimulation expanded T cells were rested in RPMI-1640 + 5 % human AB-serum without IL-2 for 2 days. 0.5-1×10e5 expanded T cells were plated with fastDCs in a ratio 1:1 of in 384-well flat bottom plates and re-stimulated for 6 h, with 1 µg/ml Brefeldin A (Sigma Aldrich) added for the last 4 hr.

Cell isolation and single-cell RNA-seq assay (10x Genomics)

838

839

840

841

842

843

844

845846

847

848

849

850

851

852

853

854 855

856

857

858

859

860

861

862

863

864 865

866

867

868

869870871

872

873874

For single cell transcriptomics, CD154+ cells were isolated by MACS and further purified by FACS sorting on a MACSQuant Tyto (Miltenyi Biotec) based on dual expression of CD154 and CD69. Sorted CD154+ T cells were removed from the sorting chamber into pre-coated low-bind collection tubes, 1ml RPMI1640 medium supplemented with 5% AB Serum was added, and cells were centrifuged for 5 min at 400 x g, 4°C. The supernatant was carefully removed leaving 10-30 μ l to reach a maximum concentration of 1000 cells / μ l.

Single-cell suspensions were loaded on a Chromium Chip G (10x Genomics) according to the manufacturer's instructions for processing with the Chromium Next GEM Single Cell 5' Library and Gel Bead Kit v1.1. Depending on the number of cells available for each patient, a maximum of 30,000 cells were loaded for each reaction. TCR single-cell libraries were subsequently prepared from the same cells with the Chromium Single Cell V(D)J Enrichment Kit, Human T Cell. Libraries were sequenced on Illumina NovaSeq 6000 machine with 2x100 bp for gene expression, aiming for 50,000 reads per cell and 2x150 bp and 5000 reads per cell for TCR libraries.

Single cell T cell receptor (TCR) sequence analysis

Single-cell T-cell receptor repertoire clonotype tables were generated using the VDJ command of the Cellranger software, version 3.1.0. from 10xGenomics and using the reference GRCh38 version 2.0.0. Clonotype tables were filtered in order to include only cells which passed quality

filtering in the gene expression analysis. In addition, clonotypes were stringently filtered for possible doublets by removing clonotypes (i) found in 1 cell only and containing more than 1 TCR alpha and 1 TCR beta (ii) containing more than 1 TCR alpha and no TCR beta sequence (iii) containing more than 1 TCR beta and no TCR alpha sequence (iv) containing more than 2 TCR alpha or more than 2 TCR beta sequences.

Alpha diversity measures were calculated for each patient either for the whole repertoire or divided based on Seurat clusters. R packages "vegan" and "tcR" were used to calculate the Inverse Simpson diversity index and the Gini inequality index, respectively. For these analyses samples were normalized by selection of the most abundant 50 clonotypes in order to remove the impact of different sample sizes (number of cells per sample) and to analyze only the distribution of the most expanded clonotypes.

Analysis of the most expanded clonotypes was conducted by selecting the 3 most expanded clonotypes per sample. To evaluate potentially existing preferential cumulation of most expanded clonotypes in certain functional clusters, the proportion of cells carrying these clonotypes falling in each distinct Seurat cluster was calculated.

Single-cell transcriptome analysis

The preprocessing of the scRNA-data was performed with the 10x Genomics' Cell Ranger software v3.1.0 using the reference GRCh38 v3.0.0 for the mappings. The resulting filtered feature-barcode matrix files were analyzed with the R package Seurat v.3.2.0 (Butler et al., 2018). Thereby, all genes with a detected expression in less than 0.1% of the non-empty cells were excluded. Moreover, TCR genes were not considered for further analyses to avoid functional clustering of cells based on TCR information. To minimize the number of doublets, empty cells, and cells with a transcriptome in low quality, only cells harboring between 840 (minimum median among samples) and 3000 RNA features and less than 5% mitochondrial RNA were selected for further processing. Afterwards, data were log-normalized and scaled based on all genes. After performing a PCA dimensionality reduction (20 dimensions) with the RunPCA function, the expression values were corrected for effects caused by different sample preparation time points in time using the R package Harmony v1.0 (Korsunsky et al., 2019). In the final steps, the Uniform Manifold Approximation and Projection (UMAP) dimensional reduction was performed with the RunUMAP function using 20 dimensions, a shared nearest neighbor graph was created with the FindNeighbors method, and the clusters identification was performed with a resolution of 0.2 using the FindClusters function. Positive cluster marker genes were determined using FindMarkers with the MAST method (Finak et al., 2015). Thereby, only genes with detected expression in at least 25% of the cells in the respective cluster were considered.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical parameters including the exact value of n, the definition of center, dispersion and precision measure, and statistical significance are reported in the Figures and the Figure Legends. Statistical tests were performed with GraphPad PRISM software 8.4 (GraphPad Software, La Jolla, CA, USA). Statistical tests were selected based on appropriate assumptions with respect to data distribution and variance characteristics, p values < 0.05 were considered statistically significant.

DATA AND SOFTWARE AVAILABILITY

Software

Flow-cytometry data were analyzed using FlowJo (Treestar, Ashland, OR, USA) software. Graphics and statistics were created with GraphPad PRISM software version 8.4.3. (GraphPad Software, La Jolla, CA, USA). Heatmaps were generated using Genesis software (Sturn et al., 2002), version 1.7.7.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure S1








Figure S2




Figure S3




Figure S4






Figure S5




Figure S6




Table S1. Cohort characteristics

	COVID-19 (n=49)	Unexposed (n=50)
Age mean	51 years (range 22-88)	39 years (range 22-61)
Gender		
Male	53% (26/49)	32% (16/50)
Female	47% (23/49)	68% (34/50)
Disease Severity ^a		
Non-hospitalized (WHO 1-2)	53% (26/49)	NA
Mild-moderate (WHO 3-5)	25% (12/49)	NA
Severe (WHO 6-7)	22% (11/49)	NA
SARS-CoV PCR positive		
Non-hospitalized (WHO 1-2)	81% (21/26)	NA
Mild-moderate (WHO 3-5)	100% (12/12)	NA
Severe (WHO 6-7)	100% (11/11)	NA
Total	90% (44/49)	NA
Antibody test positive ^b		
Non-hospitalized (WHO 1-2)	100% (26/26)	NA
Mild-moderate (WHO 3-5) ^{b, c}	75% (9/12)	NA
Severe (WHO 6-7)	100% (11/11)	NA
Total	94% (46/49)	0% (0/50)

a WHO criteria

NA=not applicable

^b Elecsys Anti-SARS-CoV-2, Roche Diagnostics GmbH ^c Anti-SARS-CoV-2 ELISA, Euroimmun